Online inquiry

IVTScrip™ mRNA-Anti-IL17A&IL17F, MCAF-5352A(Cap 1, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ10961MR)

This product GTTS-WQ10961MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & Pseudo-UTP. It ecodes the monoclonal antibody that targets IL17A&IL17F gene. The antibody can be applied in Multiple sclerosis (MS) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_002190.3; NM_052872.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3605; 112744
UniProt ID Q16552; Q96PD4
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL17A&IL17F, MCAF-5352A(Cap 1, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ10961MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ7719MR IVTScrip™ mRNA-Anti-GLP1R, GLP-1Fc(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA GLP-1Fc
GTTS-WQ3893MR IVTScrip™ mRNA-Anti-PDCD1, BCD-100(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA BCD-100
GTTS-WQ11063MR IVTScrip™ mRNA-Anti-EGFR&LGR5, MCLA-158(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA MCLA-158
GTTS-WQ5435MR IVTScrip™ mRNA-Anti-tcdA, CDA 1(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA CDA 1
GTTS-WQ11138MR IVTScrip™ mRNA-Anti-IFNA1, MDX-1103(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA MDX-1103
GTTS-WQ265MR IVTScrip™ mRNA-Anti-EPCAM, 17-1A(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA 17-1A
GTTS-WQ9900MR IVTScrip™ mRNA-Anti-CSF2, KB-003(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA KB-003
GTTS-WQ10941MR IVTScrip™ mRNA-Anti-HAVCR2, MBG-453(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA MBG-453
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW